Co-immunoprecipitation studies demonstrated that the peptide reduces eNOS/caveolin-1 binding by approximately 50%, effectively doubling the available eNOS for nitric oxide production
Appropriate use is determined individually by a licensed medical provider based on your health profile, and it requires a prescription and clinical oversight
10.14336/AD.2019.0508 Aging Dis
We need much larger, more thorough trials to determine whether this peptide is safe or even effective to try
Obstet Gynecol 116:11711183 Hudson MM, Ness KK, Gurney JG, Mulrooney DA, Chemaitilly W, Krull KR, Green DM, Armstrong GT, Nottage KA, Jones KE et al (2013) Clinical ascertainment of health outcomes among adults treated for childhood cancer
Some benefit from monthly sessions, while others may need them more regularly